SCHEMBL7519340

SCHEMBL7519340

CN(C)CCn1c(-c2nc3cc(Cl)c(Cl)cc3[nH]2)cc2cc(/C=C3/SC(=O)NC3=O)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.42
ESR1 P03372 1/20 0.42
CCR2 P41597 1/20 0.39
DYRK3 O43781 1/20 0.38
PPARG P37231 3/20 0.38
PIM1 P11309 3/20 0.37
PIM2 Q9P1W9 3/20 0.37
GSK3B P49841 2/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
HTT P42858 1/20 0.37
PIK3CD O00329 1/20 0.36
CSNK2A2 P19784 1/20 0.36
MAOB P27338 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7519343 1.00 IGF1R (0.42) IGF1RESR1CCR2DYRK3PPARG
SCHEMBL7520438 0.89 IGF1R (0.43) IGF1RESR1PIM1PIM2MGAM
SCHEMBL7520443 0.89 IGF1R (0.43) IGF1RESR1PIM1PIM2MGAM
SCHEMBL7516068 0.86 IGF1R (0.48) IGF1RESR1PIM1PIM2MGAM
SCHEMBL7516066 0.86 IGF1R (0.48) IGF1RESR1PIM1PIM2MGAM
SCHEMBL7514695 0.82 IGF1R (0.40) IGF1RDYRK3PIM1PIM2GSK3B
SCHEMBL7514689 0.82 IGF1R (0.40) IGF1RDYRK3PIM1PIM2GSK3B
SCHEMBL7518345 0.77 HPGD (0.41) IGF1RPPARGPIM1PIM2MGAM
SCHEMBL7518342 0.77 HPGD (0.41) IGF1RPPARGPIM1PIM2MGAM
SCHEMBL7556207 0.76 MGAM (0.55) IGF1RDYRK3PIM1PIM2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 IGF1R 1097/4885ESR1 1933/4885CCR2 4250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.